Off-Label Debate Between FDA, Industry To Formally Begin After Election
After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.
You may also be interested in...
Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.
Jennifer Corrigan-Curay joins from the National Heart, Lung and Blood Institute, where she worked on clinical trial initiatives and served as an NIH representative on FDA’s Drug Safety Oversight Board.
Pfizer attorney raises impact on research and other key themes for the upcoming FDA public hearing.